Table 7.
Short duration regimens.
| Study | Population | Regimen | Overall SVR12 | Cirrhotic SVR12 |
|---|---|---|---|---|
| NIAID SYNERGY (6 or 12 weeks) | GT1, TN, cirrhosis allowed | SOF/LDV, 12 weeks | 100% | 100% |
| (20/20) | (3/3) | |||
| GT1, TN, noncirrhotic | SOF/LDV/GS-9669, 6 weeks | 95% | n/a | |
| (19/20) | ||||
| GT1, TN, noncirrhotic | SOF/LDV/VDR, 6 weeks | 100% | n/a | |
| (20/20) | ||||
| BMS FOURWARD (4 or 6 weeks) | GT1, TN, noncirrhotic | DCV/ASV/BMS-791325 + SOF, 4 weeks | Pending | n/a |
| GT1, TN, noncirrhotic | DCV/ASV/BMS-791325 + SOF, 6 weeks | Pending | n/a |
ASV, asunaprevir; DCV, daclatasvir; GT, genotype, SOF, sofosbuvir; TN, treatment naïve; LDV, ledipasvir; n/a, not applicable; VDR, vedroprevir.